Tempus AI, Inc. (TEM)
What's Fueling Tempus AI's Explosive Sales Growth?
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
Tempus AI: High-Growth And High-Risk
Tempus AI offers a compelling vision in precision oncology, boasting strong data assets, strategic partnerships, and rapid revenue growth. Valuation is rich, and execution risk is high—success depends on converting AI promise into validated, reimbursed diagnostics and sustainable cash flow. Tempus is a high-risk, high-reward play; I rate it a Hold, suitable only for speculative investors with a long-term, risk-tolerant outlook.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Tempus AI Is Well Worth Its Price Tag
Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI healthcare space. Strong innovation is clearly translating into their financial metrics as revenue growth and margin expansion are promising signs. Guidance was strong as revenue growth is expected to accelerate and the company expects to be adjusted EBITDA positive this year.
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
Tempus AI TEM surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors' positive reaction to two back-to-back innovations from the company.
I'm Still Bullish On Tempus AI
TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM's main bet is now on AI for healthcare applications. I believe TEM's main business moat is its vast and rapidly growing data, which can be leveraged for AI. This is how TEM has sustained its impressive revenue growth. For example, it's integrating Ambry and Deep 6 to expand hereditary testing and add millions of records to its dataset. This strengthens Tempus AI's use cases.
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
Tempus AI: Firing On All Cylinders
Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% YoY, but headline growth topped 75% due to the Ambry deal, though organic growth analysis is crucial for investors. The stock trades at a reasonable 7x '26 sales with 25-28% pro forma growth, but limited adjusted EBITDA targets may cap the valuation premium.
Tempus AI: I Believe In The Company's Cause
I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though profitability and high debt remain concerns as it integrates recent acquisitions. Tempus AI's vast clinical and molecular data, validated at major conferences, positions it as a key partner for leading pharma and healthcare companies.
